Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Polynovo ( (AU:PNV) ) has provided an announcement.
PolyNovo has reported a strong financial year with significant growth in commercial sales and regulatory clearances, expanding its market reach to 46 countries. The company is poised for further growth with the upcoming commercialization of new products and anticipated pricing reforms, supported by a robust cash position and strategic leadership changes.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
More about Polynovo
PolyNovo is a company operating in the medical device industry, primarily focusing on the development and commercialization of NovoSorb products for complex wound management. The company has expanded its market presence to 46 countries and is known for its innovative solutions in the field of wound care.
Average Trading Volume: 3,547,644
Technical Sentiment Signal: Sell
Current Market Cap: A$894.6M
For a thorough assessment of PNV stock, go to TipRanks’ Stock Analysis page.